516
Views
23
CrossRef citations to date
0
Altmetric
Original Article

Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome

, , , , , , , , , , , , , , , , & show all
Pages 150-154 | Received 17 Jun 2015, Accepted 18 Apr 2016, Published online: 20 Jun 2016

References

  • McCarty DJ, O’Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. JAMA. 1985;254:2763–7.
  • Russell EB, Hunter JB, Pearson L, McCarty DJ. Remitting seronegative symmetrical synovitis with pitting edema – 13 additional cases. J Rheumatol. 1990;17:633–9.
  • Sibilia J, Friess S, Schaeverbeke T, Maloisel F, Bertin P, Goichot B, et al. Remitting seronegative synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis? J Rheumatol. 1999;26:115–20.
  • Origuchi T, Arima K, Kawashiri SY, Tamai M, Yamasaki S, Nakamura H, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Modern Rheumatol. 2012;22(4):584–8.
  • Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol. 1999;17(6):741–4.
  • Cantini F, Salvarani C, Olivieri I, Barozzi L, Macchioni L, Niccoli L, et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis. 1999;58(4):230–6.
  • Olivé A, del Blanco J, Pons M, Vaquero M, Tena X. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalán Group for the Study of RS3PE. J Rheumatol. 1997;24(2):333–6.
  • Do-Nguyen D, Inderjeeth CA, Edelman J, Cheah P. Retrospective analysis of the clinical course of patients treated for polymyalgia. Open Access Rheumatol: Res Rev. 2013;5:33–41.
  • Kimura M, Tokuda Y, Oshiawa H, Yoshida K, Utsunomiya M, Kobayashi T, et al. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol. 2012;39(1):148–53.
  • Cleuziou C1, Binard A, De Bandt M, Berthelot JM, Saraux A. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol. 2012;39(2):310–13.
  • Kermani TA1, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013;381(9860):63–72.
  • Binard A, De Bandt M, Berthelot JM, Saraux A; Inflammatory Joint Disease Working Group CRI of the French Society for Rheumatology. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum. 2007;57(3):481–6.
  • Ungprasert P, Sanguankeo A, Upala S, Knight EL. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(3):366–70.
  • Muller S, Hider SL, Belcher J, Helliwell T, Mallen CD. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis. 2014;73(10):1769–73.
  • Myklebust G1, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29(10): 2143–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.